Beta-blockers (β-blockers)

Beta-blockers constitute one of the most critical and frequently utilized therapeutic classes in cardiology. Their primary mechanism of action involves inhibiting the effects of adrenaline and noradrenaline on the myocardium, subsequently reducing both heart rate and arterial blood pressure.

In the management of cardiac arrhythmias, their fundamental function is to decelerate electrical impulse transmission through the atrioventricular (AV) node (the electrical junction connecting the atria to the ventricles). By exerting this effect, they protect the myocardium from tachyarrhythmias and dangerously elevated heart rates.

Which medications belong to this class?
In daily clinical practice, various beta-blockers are selected based on the specific clinical requirements of each patient. The most commonly prescribed agents include:

  • Bisoprolol
  • Metoprolol
  • Atenolol
  • Carvedilol
  • Nebivolol
  • Propranolol
  • Esmolol (administered exclusively via the intravenous route in hospital settings for acute, emergent situations)

Primary Indications (When are they indicated for arrhythmias?)
According to current cardiovascular clinical guidelines, beta-blockers are essential for:

  1. Atrial Fibrillation and Atrial Flutter: They represent the global first-line therapeutic choice for "rate control". Although they do not consistently terminate the arrhythmia, they impede irregular atrial impulses from propagating to the ventricles, thereby maintaining the ventricular rate within safe parameters.
  2. Prevention of Tachycardias: They are utilized to prevent and terminate episodes of supraventricular tachycardias.
  3. Premature Complexes: They exhibit high efficacy in suppressing atrial and ventricular premature complexes, relieving patients from the distressing sensation of palpitations or a skipped heartbeat.
  4. Post-Myocardial Infarction Protection & Heart Failure Management: They significantly reduce the incidence of life-threatening ventricular arrhythmias and protect against sudden cardiac death. According to recent clinical data, long-term administration post-myocardial infarction is lifesaving if the myocardium has sustained structural damage (reduced ejection fraction) or if the patient presents with arrhythmias.

Adverse Effects (What should the patient monitor?)
Although generally safe, they may induce the following adverse effects in certain patient populations:

  • Bradycardia: Excessive reduction of the heart rate (below 50–55 beats per minute).
  • Fatigue or Dizziness: Resulting from arterial hypotension or bradycardia.
  • Exacerbation of Asthma: They can induce bronchospasm; therefore, they are contraindicated or avoided in patients with severe respiratory disease.
  • Erectile Dysfunction: A recognized adverse effect that frequently concerns male patients.

Critical Patient Instruction:
Beta-blockers must never be discontinued abruptly by the patient. Sudden cessation can precipitate a rebound effect, leading to an acute and dangerous elevation in heart rate (tachycardia), rebound hypertension, or an acute anginal crisis. Discontinuation or dosage modification must always be performed gradually and strictly under the supervision of a cardiologist.

2026-11-18T22:40:56+00:00